Research-literacy siteEducational evidence reviews only — not medical advice, not dosing guidance, not a protocol for human or animal use. Medical disclaimer.

PeptideStacks

Mitochondrial-Derived Peptides Mechanism Map

An organelle that codes for its own signalling molecules — what reviews report about how MOTS-c, humanin and the SHLPs are encoded and what they do in cells and animals.

Educational research-literacy content only. Not medical advice, not dosing guidance, not sourcing advice, and not a protocol for human or animal use. See our responsible information policy.

Not every peptide is nuclear-encoded

Most peptides your body produces are coded in the nucleus. A small class is coded inside mitochondrial DNA (mtDNA). A 2020 review counts eight of these mitochondrial-derived peptides (MDPs): MOTS-c, encoded in the 12S ribosomal RNA gene (MT-RNR1), and humanin plus the small humanin-like peptides SHLP1–6, encoded in the 16S ribosomal RNA gene (Merry 2020, PMID 32776825). A 2023 review calls humanin one of nine MDPs, so the count differs between reviews (PMID 37106758).

The three families

Humanin

24 amino acids, encoded by a short open reading frame within the 16S rRNA gene MT-RNR2, according to a 2023 systematic review (PMID 37106758). Humanin was first reported in 2001 from a cDNA. In a correction published later that year, the authors wrote that “[t]here is no proof that the HN cDNA represents a gene, that its origin is nuclear, or that the HN peptide is produced in vivo”; see the humanin monograph.

Receptors: the 2023 review describes humanin as a ligand of FPRL1 (formyl peptide receptor-like 1), with ERK1/2 activation linked to cell survival, and of a CNTFR/gp130/WSX-1 complex that leads to JAK2 and STAT3 phosphorylation. FPRL1 is the older name of the receptor now called FPR2/ALX, and FPRL2 is the older name of FPR3 (IUPHAR nomenclature, Ye 2009, PMID 19498085). The review also summarises a study reporting that humanin’s interaction with FPRL1 and FPRL2 protects neurons from amyloid-beta.

Reported effects: cytoprotection. The review describes protection of cultured neurons from amyloid-beta toxicity and, in aged mice, reversal of cardiomyocyte apoptosis with the HNG analogue. These are cell and animal findings. In a 2020 mouse study of triple-negative breast cancer, systemic humanin “reduced tumor apoptotic rate, impaired the antitumor and anti-metastatic effect of chemotherapy and stimulated tumor progression, accelerating tumor growth and development of spontaneous lung metastases”; the authors conclude that “caution should be taken when using exogenous HN to treat degenerative diseases” (Moreno Ayala 2020, PMID 32444831).

SHLPs 1–6

Six further peptides found by an in silico search of the same 16S region as humanin (Cobb 2016, PMID 27070352). In that study the SHLPs differed in their effect on cell viability in vitro. SHLP2 and SHLP3 shared humanin’s protective effects in cells, intracerebrally infused SHLP2 increased glucose uptake and suppressed hepatic glucose production in clamp studies, and circulating SHLP2 was found to decrease with age.

MOTS-c

16 amino acids, encoded by a short open reading frame within the 12S rRNA gene MT-RNR1 (Lee 2015, PMID 25738459).

Mechanism: the 2015 paper’s abstract reports that its cellular actions “inhibit the folate cycle and its tethered de novo purine biosynthesis, leading to AMPK activation”. The abstract does not name a cell-surface receptor.

Reported effects: in mice, MOTS-c treatment “prevented age-dependent and high-fat-diet-induced insulin resistance, as well as diet-induced obesity”, and its primary target organ “appears to be the skeletal muscle”. The abstract does not print a dose.

What reviews say links them

  • Signalling beyond the cell. The 2020 review says MDPs “appear to form an important aspect of a retrograde signaling network that communicates mitochondrial status with the wider cell and to distal tissues”. The 2023 review notes humanin can be found in plasma, cerebrospinal fluid and seminal fluid, and that it is unclear which tissues supply the circulating pool or how it is released.
  • Age. The 2023 review says circulating humanin levels, “according to conflicting studies”, decrease with age in mice and humans. In Cobb 2016 (PMID 27070352), circulating SHLP2 decreased with age. The 2020 review reports that obesity, diabetes and ageing are associated with lower circulating MDPs, while human muscle MDP expression rises with stress such as exercise and with healthy ageing.
  • Exercise. In a randomised study of acute exercise, acute endurance exercise raised circulating humanin, MOTS-c showed “a trend to increase”, and acute resistance exercise did not raise MDP levels (von Walden 2021, PMID 34351816). In 10 young men cycling, circulating MOTS-c rose 1.6-fold during and 1.5-fold after exercise (Reynolds 2021, PMID 33473109). These measure the body’s own peptides; they do not show an effect of giving a peptide.

Not to be confused with mitochondria-targeted synthetics

SS-31 / elamipretide is a different category. It is a tetrapeptide drug, not one encoded in mtDNA. A 2022 review describes it as a “water-soluble, aromatic-cationic, mitochondria-targeting tetrapeptide that readily penetrates and transiently localizes to the inner mitochondrial membrane” and says it “becomes associated with cardiolipin” (Sabbah 2022, PMID 34623544). The MDPs are peptides encoded in the body’s own mtDNA.

Both categories concern mitochondrial function, but they operate at different levels. See our SS-31 vs MOTS-c comparison for a side-by-side breakdown of the two approaches.

Regulatory context

This site gives no legal advice or sourcing information and does not sell anything. Rules on unauthorised medicines exist in the Human Medicines Regulations 2012. Whether a particular product is a medicinal product under regulation 2 depends on its specifics, including how it is presented and how it functions. For questions about medicines speak to a GP or pharmacist; problems with a medicine can be reported to the MHRA through the Yellow Card scheme.

Drugs@FDA data (via openFDA, 6 November 2026) record Forzinity (elamipretide, NDA 215244) as originally approved on 19 September 2025. Its DailyMed label (version effective 10 December 2025) says it is indicated “to improve muscle strength in adult and pediatric patients with Barth syndrome weighing at least 30 kg”, under accelerated approval. See the SS-31 monograph and the regulation pages.

Related pages

Published: 2026-06-20Last updated: 2026-11-06

If you spot an error or have new evidence to suggest, please use our corrections policy.